title: Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
authors.forename: Cristina
authors.initials: C
authors.lastname: Noberasco
authors.forename: Tommaso
authors.initials: T
authors.lastname: De Pas
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Curigliano
authors.forename: Sara
authors.initials: S
authors.lastname: Manzoni
authors.forename: Lucia
authors.initials: L
authors.lastname: Dodaro
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pelosi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Spaggiari
authors.forename: Filippo
authors.initials: F
authors.lastname: De Braud
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000188:drug therapy*; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077156:Gefitinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases